ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1834

Evaluation of Fibromyalgia, Clinical/Serologic Activity, and Patient Reported Outcomes in a Racially/Ethnically Diverse SLE Patient Cohort

Kelly Corbitt1, Philip Carlucci2, Brooke Cohen3, Mala Masson3, H Michael Belmont4, Amit Saxena5, Chung-E Tseng3, Jing Wang3, Kamil Barbour6, Jill Buyon7, Peter Izmirly2 and Heather Gold3, 1New York University, El Portal, FL, 2New York University School of Medicine, New York, NY, 3New York University, New York, NY, 4NYU School of Medicine, New York, NY, 5New York University Grossman School of Medicine, Rheumatology, New York, NY, 6Centers for Disease Control and Prevention, Atlanta, GA, 7NYU Grossman School of Medicine, New York, NY

Meeting: ACR Convergence 2023

Keywords: fibromyalgia, pain, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1827–1839) Fibromyalgia & Other Clinical Pain Syndromes Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: SLE patients have a higher prevalence of fibromyalgia (FM) than the general population. FM symptoms, such as nociplastic pain and fatigue, are known to cause discordance in how patients and physicians view well-controlled SLE, and these variables impact quality of life in ways not captured by traditional disease activity scores. There is a paucity of objective data surrounding the clinical interplay of these two diseases. Given this, and emerging evidence suggesting the contribution of autoimmunity to FM, this study evaluated FM clinically, serologically, and via patient reported outcomes in a multi-racial/ethnic SLE patient cohort.

Methods: Patients from an established lupus cohort were screened for FM using the 2016 FM classification criteria during an in-person rheumatologist visit. Hybrid SELENA-SLEDAI scores, SLE classification criteria, medications, and SLICC damage index were evaluated. A portion of the patients who reported any chronic pain also completed 8 PROMIS measures. Clinical and serologic activity was compared in patients with and without FM, as well as T-score means of PROMIS measures between FM and non-FM chronic pain patients. For T-score means significantly different between groups, linear regression models adjusting for age, race/ethnicity, SELENA-SLEDAI score, and steroid use were estimated.

Results: Of 316 SLE patients completing the FM questionnaire, 55 (17%) met criteria for FM, 57 (18%) reported chronic pain without FM, and 204 (65%) had no chronic pain. The racial/ethnic composition of the FM patients was 35% White, 27% Black, 6% Asian, and 31% Hispanic, which differed from those without FM (p=0.023), primarily due to a smaller proportion of Asian patients with FM. There was no significant difference in overall SELENA-SLEDAI score. However, there was more active arthritis in the FM group versus the non-FM group (Table 1). The widespread pain index (WPI) and symptom severity score (SSS) were not correlated with current degree of SLE activity in FM or in non-FM chronic pain patients (Figure 1). Of the SLE criteria, FM patients were less likely to have ever had lupus nephritis and more likely to have malar rash. The SLICC damage index did not differ between groups. Of the 112 patients with chronic pain (plus/minus FM), 70 completed at least one PROMIS measure. Fatigue, sleep disturbance, and cognitive function were significantly worse in FM patients, whereas pain measures, depression, anxiety, and physical function did not differ between groups (Table 2). After adjusting for age, race (White/non-Hispanic), SELENA-SLEDAI score, and current steroid use, FM was associated with a 5-point increase in mean sleep disturbance and fatigue scores. Cognitive function, however, was no longer significantly associated with FM.

Conclusion: These findings underscore that symptoms associated with FM in SLE patients can be independent of chronic pain, SLE disease activity and damage, and overall suggests the need for better understanding of the biology of this group.

Supporting image 1

Figure 1. WPI and SSS do not correlate with SLEDAI in FM or non-FM chronic pain patients. A–B show the correlation between WPI (A) or SSS (B) and SLEDAI in FM patients and C–D show the correlation between WPI (C) or SSS (D) and SLEDAI in non-FM chronic pain patients.

Supporting image 2

Table 1. Clinical and serologic profiling of SLE patients with FM compared to those without FM, n=316. Demographics, current SLE manifestations via SELENA-SLEDAI, SLE classification criteria and associated antibodies, and SLICC damage index are all shown. *N is specified where it differs from overall sample size.

Supporting image 3

Table 2. PROMIS measures assessed between groups, with “worse” quality of life represented by higher scores for symptoms and lower scores for function. PROMIS T score mean for the general United States population=50 (SD=10). Minimally important difference=2–3 for PROMIS measures in patients with lupus. Non-FM chronic pain patients had n=35 in the top 4 measures of the table and n=33 for the remaining 4 measures.


Disclosures: K. Corbitt: None; P. Carlucci: None; B. Cohen: None; M. Masson: None; H. Belmont: Alexion, 6, Aurinia, 6; A. Saxena: AbbVie, 1, AstraZeneca, 1, GSK, 1; C. Tseng: None; J. Wang: None; K. Barbour: None; J. Buyon: Bristol-Myers Squibb(BMS), 2, GlaxoSmithKlein(GSK), 2, Related Sciences, 1; P. Izmirly: None; H. Gold: None.

To cite this abstract in AMA style:

Corbitt K, Carlucci P, Cohen B, Masson M, Belmont H, Saxena A, Tseng C, Wang J, Barbour K, Buyon J, Izmirly P, Gold H. Evaluation of Fibromyalgia, Clinical/Serologic Activity, and Patient Reported Outcomes in a Racially/Ethnically Diverse SLE Patient Cohort [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-fibromyalgia-clinical-serologic-activity-and-patient-reported-outcomes-in-a-racially-ethnically-diverse-sle-patient-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-fibromyalgia-clinical-serologic-activity-and-patient-reported-outcomes-in-a-racially-ethnically-diverse-sle-patient-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology